Dry Eye Disease

Executive summary

Dry eye disease (DED) is one of the most frequently encountered ocular morbidities. 25 % percent of patients who visit ophthalmic clinics report symptoms of dry eye, making it a growing public health problem and one of the most common conditions seen by eye care practitioners. Historically, the term "Keratoconjunctivitis sicca" can be attributed to the Swedish ophthalmologist Henrik SC jögren. He was the first to refer to the triad of Keratoconjunctivitis sicca, dry mouth, and joint pain, which occurs mainly in women (90% of the cases) (www.sjogrens.org), and in 1950 Andrew De Roetth introduced the term "dry eye". For many decades, DED was thought to be limited to dryness of the eyes due to reduction of the aqueous phase of the tear film. In 1995, DED was defined as a complex multifaceted group of medical and ocular diseases that is due to decreased tear production and/or increased tear evaporation. In 2007, the International Dry Eye Workshop (DEWS) revised the original definition and classification scheme of DED and developed a new definition, as well as a three‐part classification of DED based on etiology, mechanism, and severity of the disease.
See also: http://www.dry-eye-disease.com/



Table of content

1. Presentation - Global Information

   Mechanism of dry eye
   The Epidemiology of Dry Eye Disease

2. Diagnostics
   Slit-lamp Examination
   Symptom Questionnaires
   Grading Ocular Surface Staining
   Tear Film Break-up Time -TFBUT
   Reflex Tear Flow - Schirmer's Test
   Tear Osmolarity

3. Market
   Eye care Market Overview
   Dry Eye Market Overview

4. Treatment and Product
   Tear supplementation: lubricants
   Tear Retention
   Tear Stimulation: Secretogogues
   Anti-Inflammatory Therapy
   Surgical treatment

5. Products in development
   Prolacria (Inspire / Allergan / Santen)
      Clinical Data
   Rebamipide (Ostuka/ Novartis/ Acucela)
   Ecabet Sodium (ISTA Pharmaceuticals)
      Clinical Data
   Vekacia (Novagali Pharma)
      Clinical Data
   Vismed (TRB, Jamjoom / Alcon /Lantibio)
   Civamide (Opko Health)
   ST-603 (Sirion Therapeutics)
   ALTY-0501 (Alacrity Biosciences)
   AL-2178 FID109980 (Alcon)
   EGP-437 (Eyegate Pharma)
      Clinical Data
   RX-10045 (Resolvyx Pharmaceuticals)
      Clinical Data
   SAR-1118 (Sunesis Pharmaceuticals / SARcode)
      Licensing and General info
      Clinical Data

List of Figures:

Figure 1: Major etiological causes of dry eye
Figure 2: Mechanisms of dry eye
Figure 3: Dry eye cascade
Figure 4: Prevalence by age and sex
Figure 5: Schematic illustration of the relationship between dry eye and other forms of ocular surface disease (OSD); MGD = Meibomian gland dysfunction
Figure 6: Global segment size of the ophthalmologic market in 2008 (*including lens care, OTC and contact lens)
Figure 7: Pharmaceuticals segment growth of the ophthalmology market ($m)
Figure 8: Global leader in eye care 2006 sales (market shares)
Figure 9: The six main therapeutic segments of the ophthalmology market by market share
Figure 10: Dry Eye market growth ($m) for years 2006 through 2014
Figure 11: Global market for dry eye products by region ($m)
Figure 12: Restasis sales in $ million (forecasts 2009-2014)

List of Tables:

Table 1: Summary of population-based epidemiologic studies of dry eye
Table 2: Practical sequence of tests
Table 3: Symptom questionnaires in current use
Table 4: Alphabetical listing of tests used to diagnose and monitor dry eye
Table 5: Eye care market segments
Table 6: Dry eye menu of treatments
Table 7: Treatment recommendations by dry eye severity level
Table 8: Low viscosity lubricants
Table 9: High viscosity lubricants
Table 10: Unknown viscosity lubricants
Table 11: Artificial Tear Products From Alcon, Allergan and Bausch & Lomb
Table 12: Lacrisert® Description - DED Prescription Ophthalmologic Drugs
Table 13: Hypertonic ointments (sodium chloride 5.0%)
Table 14: Petrolatum/Mineral oil ointments
Table 15: Silicone punctal plugs
Table 16: Silicone Intracanular Plugs
Table 17: Silicone Intracanular Plugs
Table 18: Moisture Chamber Spectacles
Table 19: Restasis® Description - DED Prescription Ophthalmologic Drugs
Table 20: List of products in development
Table 21: Prolacria (Diquafosol tetrasodium)
Table 22: Rebamipide Last Clinical Trials
Table 23: Ecabet Last Clinical Trials
Table 24: Vekacia Last Clinical Trials
Table 25: ST-603 Last Clinical Trials
Table 26: ALTY-0501 Last Clinical Trial
Table 27: AL-2178 FID109980 Last Clinical Trial
Table 28: EGP-437 Last Clinical Trial
Table 29: RX-10045 Last Clinical Trial
Table 30: SAR-1118 Last Clinical Trial

See also http://www.dry-eye-disease.com/



Publication date: Number of pages: Price:
2009-12-01 62 4500 euros